# Treating a Specific Lymphoma with Modified T Cells > This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient. - **Patent:** US 12600775 - **Original title:** Chimeric antigen receptor T cell therapy - **Owner:** Kite Pharma - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, gene_editing, immunotherapy ## What it does This patent outlines a method for treating relapsed or refractory mantle cell lymphoma (MCL) in patients who have specific tumor characteristics, either a Ki-67 tumor proliferation index of 50% or higher, or a TP53 gene mutation (Claim 1). The treatment involves collecting a patient's own (autologous) T cells from their blood, enriching them for specific types (CD4+ and CD8+), and removing any circulating cancer cells (Claim 1). These T cells are then engineered to express a "chimeric antigen receptor" (CAR) that specifically targets a protein called CD19, using a particular anti-CD19 component called FMC63 (Claim 1). Before receiving these modified T cells, patients may get a "bridging therapy" and a "lymphodepleting chemotherapy" to prepare their body (Claims 5, 7). ## What it does NOT cover - Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (Claim 1). - Does not cover CAR T cell therapies that use T cells from a donor (allogeneic) rather than the patient's own (autologous) cells (Claim 1). - Does not cover CAR T cells designed to target cancer markers other than CD19, or those using a different anti-CD19 component than the FMC63 single-chain variable fragment (scFv) (Claim 1). - Does not cover CAR T cells prepared without the specific steps of positive enrichment and partial or complete depletion of circulating cancer cells from peripheral blood mononuclear cells (Claim 1). - Does not cover CAR T cells that use different intracellular signaling regions than the specified CD28 and CD3-zeta domains (Claim 1). ## The clever bit The novelty lies in precisely defining the patient population (relapsed/refractory MCL with specific genetic markers) and the exact CAR T cell construct and preparation method (autologous, anti-CD19 FMC63 scFv, CD28/CD3-zeta signaling, specific enrichment/depletion) to improve outcomes for these challenging cases. ## Real-world examples 1. Yescarta (axicabtagene ciloleucel, developed by Kite Pharma/Gilead Sciences) 2. Other CD19-targeted CAR T cell therapies for lymphoma 3. Clinical trials for CAR T cell therapies in relapsed/refractory MCL ## Why it matters Mantle cell lymphoma (MCL) is an aggressive blood cancer that is often difficult to treat, especially after initial therapies fail. This patent focuses on a specific, challenging subset of MCL patients, offering a new approach using genetically engineered T cells. Kite Pharma, the assignee, is a major player in the CAR T cell therapy field, having developed one of the first approved CAR T cell treatments. This patent aims to refine and expand the application of this powerful technology for a critical patient population. ## Frequently asked questions ### What does Treating a Specific Lymphoma with Modified T Cells cover? This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient. ### Who owns patent US 12600775? Kite Pharma owns this patent, granted in 2026. ### When does this patent expire? This patent is expected to expire on November 6, 2040, when the invention enters the public domain. ### What problem does this patent solve? Mantle cell lymphoma (MCL) is an aggressive blood cancer that is often difficult to treat, especially after initial therapies fail. This patent focuses on a specific, challenging subset of MCL patients, offering a new approach using genetically engineered T cells. Kite Pharma, the assignee, is a major player in the CAR T cell therapy field, having developed one of the first approved CAR T cell treatments. This patent aims to refine and expand the application of this powerful technology for a critical patient population. ### What does this patent NOT cover? Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (Claim 1). **Full plain-English explainer:** https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy **Original patent:** https://patents.google.com/patent/US12600775 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How Genetically Modified T-Cells Attack Cancer](https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer) — This patent describes how human T cells are genetically engineered to express a special receptor (CAR) that specifically targets and kills cancer cells, particularly those with the CD19 marker, offering a new way to treat cancer. - [How Genetically Modified T-Cells Fight CD19 Cancers](https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer) — This patent describes how to create and use genetically modified human T cells that target and kill cancer cells expressing the CD19 protein, offering a new way to treat blood cancers. - [Targeting Cancer with CAR T Cells Using a Chemical Tag](https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy) — This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that recognize a chemical tag, which is attached to a small drug molecule, along with a separate folate compound. - [Targeting Cancer with CAR T Cells Using Small Molecule 'Flags'](https://patentbrief.org/patent/us/20250171803/methods-and-compositions-for-car-t-cell-therapy) — This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that are trained to find a specific 'flag' molecule, and then also giving them a drug molecule attached to that same 'flag' in varying amounts or forms. - [Predicting and Treating Dangerous Side Effects in CAR T-Cell Therapy](https://patentbrief.org/patent/us/12163952/determining-toxicity-risk-in-car-t-cell-therapy) — This patent describes methods to identify patients at high risk for severe side effects, like cytokine release syndrome or neurotoxicity, during CAR T-cell cancer therapy and how to treat them proactively.